0420 O3CO

Docket No.: PA-0039 US

I hereby certify that this correspondence is using deposited with the United States Postal Service as an all mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on \_\_\_\_\_\_ February 2,2002

оп <u>ге</u> Ву: <u> </u>

Printed:

Debbie Ellis

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Cunningham et al.

Title:

MARKER GENES RESPONDING TO TREATMENT WITH TOXINS

Serial No.:

10/006,285

Filing Date:

December 05, 2001

Examiner:

To Be Assigned

Group Art Unit:

To Be Assigned

Commissioner for Patents Washington, D.C. 20231

## INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.

It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual

Docket No.: PA-0039 US

of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. **09-0108**.

If there are any questions regarding the above, the Examiner is invited to call the undersigned at 650-855-0555.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: Telimony 27, 2002

Lynn E. Murry, Ph.D. Reg. No. 42,918

Direct Dial Telephone: (650) 845-4159

3160 Porter Drive

Palo Alto, California 94304

Phone: (650) 855-0555 Fax: (650) 845-4166

U.S. Depar	tment	of Commerce, I	Atty Do	Atty Docket No.		Serial No.			
					PA-0039	us	10/006,	285	
		OF REFERENCES C	Applicant(s)						
		e <b>Sev</b> eral shee	Cunningham et al.						
MOR G B YOUR EN					Filing	Date	Group		
						er 5, 2001	To Be A	Assigned	
U.S. Patent Documents									
*Examiner Initial		Document Number	Date	Name	Class	Subclass	_	Filing Date If Appropriate	
	<u> </u>							<u> </u>	
			Foreig	n Patent Documents	3				
	<del></del>	1					Trans]	lation	
	<u> </u>	Document	Date	Country	Class	Subclass	Yes	No	
	<u></u>								
	TO T	THER ART (In	cluding Auth	nor, Title, Date, F	Pertinen	t Pages, Et	c.)		
	1	Qu, S. and N.H. Stacey, "Formation and persistence of DNA adducts in different target tissues of rats after multiple administration of benzo[a]pyrene", Carcinogenesis, 17:53-59 (1996).							
	2	Kröger, H. et al., "Protection From Acetaminophen-Induced Liver Damage by the Synergistic Action of Low Doses of the Poly(ADP-ribose) Polymerase-Inhibitor Nicotinamide and the Antioxidant N-Acetylcysteine or the Amino Acid L-Methionine", Gen. Pharmac., 28:257-263 (1997).							
	3	Hasmall, S.C. and R.A. Roberts, "The Perturbation of Apoptosis and Mitosis by Drugs and Xenobiotics", <a href="Pharmacol.Ther.">Pharmacol. Ther.</a> , 82:63-70 (1999).							
	4	Gelman, L. et al., "An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer", CMLS, 55:932-943 (1999).							
	5	Kawashima, H. et al., "Protein Expression, Characterization, and Regulation of CYP4F5 and CYP4F5 Cloned from Rat Brain", <a href="Arch. Biochem. Biophys.">Arch. Biochem. Biophys.</a> , 347:148-154 (1997).							
	6	Zhou, S. and K.B. Wallace, "The Effect of Peroxisome Proliferators on Mitochondrial Bioenergetics", <u>Toxicol. Sci.</u> , 48:82-89 (1999).							
	7	Waterfield, C.J. et al., "Investigations into the effects of various hepatotoxic compounds on urinary and liver taurine levels in rats", <a href="https://example.com/Arch.254">Arch.254</a> (1993).							
	8	Pohjanvirta, R. et al., "Han/Wistar Rats are Exceptionally Resistant to TCDD. I", <a href="Pharmacol.Toxicol.">Pharmacol. Toxicol.</a> , 60:145-150 (1987).							
Examiner	_		Date Conside	ered					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.									

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

PER	<b>)</b> 9	Pohjanvirta, R. and J. Tuomisto, "Han/Wistar Rats Are Exceptionally Resistant to TCDD. II.", <u>Arch. Toxicol.</u> , Suppl. 11:344-347 (1987).					
MAR D B TOTAL	TE GET	Pohjanvirta, R. et al., "Studies on the Role of Lipid Peroxidation in the Acute Toxicity of TCDD in Rats", <a href="Pharmacol.Toxicol.">Pharmacol.Toxicol.</a> , 66:399-408 (1990).					
CATEMT & TRACE	11	Pohjanvirta, R. et al., "Target tissue morphology and serum biochemistry following 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) exposure in a TCDD-susceptible and a TCDD-resistant rat strain", Fundam. Appl. Toxicol., 12:698-712 (1989)abstract only.					
	12	Pohjanvirta, R. et al., "Physicochemical Differences in the AH Receptors of the Most TCDD-Susceptible and the Most TCDD-Resistant Rat Strains", <u>Toxicol. Applied Pharmacol.</u> , 155:82-95 (1999).					
Examiner		Date Considered					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.							